risedronic acid has been researched along with zoledronic acid in 121 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 44 (36.36) | 29.6817 |
| 2010's | 59 (48.76) | 24.3611 |
| 2020's | 18 (14.88) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Bakalara, N; Broderick, E; Chan, JM; Docampo, R; Faelens, S; Kotsikorou, E; Oldfield, E; Song, Y; Tovian, Z | 1 |
| Haase, C; Koscielski, LA; Leon, A; Oldfield, E; Song, Y; Studer, D; Zhang, Y | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Cao, R; Chang, TH; Chen, CK; Guo, RT; Hudock, MP; Jeng, WY; Ko, TP; Kuo, CJ; Liang, PH; Oldfield, E; Song, Y; Wang, AH; Yin, F; Zhang, Y | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| Cass, LM; Chang, TK; Mukkamala, D; No, JH; Oldfield, E | 1 |
| Arrowood, MJ; Artz, JD; Chruszcz, M; Dong, A; Dunford, JE; Ebetino, FH; Hui, R; Kavanagh, KL; Minor, W; Oppermann, U; Russell, RG | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Berlicki, Ł; Kafarski, P; Mucha, A | 1 |
| Berghuis, AM; De Schutter, JW; Huang, XF; Lin, YS; Park, J; Sebag, M; Tsantrizos, YS | 1 |
| Berghuis, AM; De Schutter, JW; Leung, CY; Park, J; Sebag, M; Tsantrizos, YS | 1 |
| Berghuis, AM; De Schutter, JW; Gormley, P; Hu, Z; Leung, CY; Lin, YS; Park, J; Poirier, J; Tsantrizos, YS | 1 |
| Berghuis, AM; Chiu, W; Cho, H; De Schutter, JW; Gritzalis, D; Lacbay, CM; Lin, YS; Park, J; Tsantrizos, YS; Zielinski, M | 1 |
| Cao, R; Liu, YL; Oldfield, E; Wang, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agamennone, M; Angelelli, M; Cellamare, S; Dimiccoli, V; Laghezza, A; Marobbio, CMT; Perna, F; Profilo, E; Purgatorio, R; Savino, S; Scala, R; Scilimati, A; Tolomeo, A; Tortorella, P; Toscano, A; Tricarico, D; Vitale, P | 1 |
| Bhuiyan, NH; Holstein, SA; Varney, ML; Wiemer, DF | 1 |
| Abdelmagid, WM; Mahmoodi, N; Tanner, ME | 1 |
| Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Reid, IR | 2 |
| Hershman, D; Narayanan, R | 1 |
| Chapurlat, RD | 1 |
| Brown, JP; Fraser, W; Hosking, D; Luchi, M; Lyles, K; Mesenbrink, P; Miller, P; Pak, J; Reid, IR; Richardson, P; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Liel, Y | 1 |
| De Filippo, G; Mossetti, G; Rendina, D | 1 |
| Füessl, HS | 1 |
| Hosking, D | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Aldrich, W; Harris, KW; Merrell, MA; Millender-Swain, T; Selander, KS; Triozzi, P; Wakchoure, S | 1 |
| Dunford, JE; Ebetino, FH; Guo, K; Kavanagh, KL; Knapp, S; Oppermann, U; Rogers, MJ; Russell, RG; Wu, X | 1 |
| Krane, SM | 1 |
| Brown, JP; Curiel, MD; Devogelaer, JP; Eriksen, EF; Fashola, T; Fraser, WD; Hooper, M; Hosking, D; Lyles, K; Miller, P; Pak, J; Reid, IR; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Mukherjee, S; Oldfield, E; Song, Y | 1 |
| Abelson, A | 1 |
| Barnett, BL; Deprèle, S; Ebetino, FH; Evdokimov, A; Hogan, JM; Kashemirov, BA; McKenna, CE | 1 |
| Martens, MG; Shaw, H | 1 |
| Hochberg, MC | 1 |
| Okazaki, R | 1 |
| Matsumoto, T | 1 |
| Bilezikian, JP | 1 |
| Bilezikian, JP; Gennari, L | 1 |
| Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN | 1 |
| Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Lawson, MA; Locklin, RM; Phipps, RJ; Russell, RG; Triffitt, JT; Xia, Z | 1 |
| Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Henry, C; Jahnke, W | 1 |
| Maricic, M | 1 |
| Bellahcène, A; Benzaïd, I; Castronovo, V; Clézardin, P; Colombel, M; Ebetino, FH; Fournier, PG; Mönkkönen, H; Stresing, V | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| de Macedo Dossin, F; Feng, X; Freitas-Junior, LH; Hui, R; Lee, E; Liu, YL; No, JH; Oldfield, E; Wang, K; Yoo, JA; Zhang, Y; Zhu, W | 1 |
| Britton, C; Walsh, J | 1 |
| Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS | 1 |
| Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T | 1 |
| Cai, HF; Li, YT; Zhang, ZL | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Arponen, H; Haukka, J; Mäkitie, O; Valta, H; Vuorimies, I; Waltimo-Sirén, J | 1 |
| Atherton, P; Burger, K; Diekmann, B; Dueck, AC; Hines, S; Liu, H; Loprinzi, CL; Novotny, P; Perez, EA; Singh, J; Sloan, JA; Tan, A; Zhao, X | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Fernández, D; Frau, J; Mariño, L; Ortega-Castro, J; Perelló, J | 1 |
| Chen, X; Liu, C; Yang, Y; Zhang, Y; Zhong, D; Zhou, L | 1 |
| Cheung, MS | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Eiken, P; Vestergaard, P | 1 |
| Jiao, K; Kumar, S; Li, JY; Messer, R; Niu, LN; Pashley, DH; Pei, DD; Pramanik, C; Tay, FR; Yuan, H | 1 |
| Auriola, S; Määttä, JA; Mönkkönen, J; Zlatev, HP | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Inderjeeth, AJ; Inderjeeth, CA; Raymond, WD | 1 |
| Bell, JM; Beringer, T; Blackwood, B; Elliott, M; Hamilton, A; Quinlivan, R; Shields, MD; Tirupathi, S; Watters, J | 1 |
| Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L | 1 |
| Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y | 1 |
| Albert, SG; Reddy, S | 1 |
| Liel, Y; Plakht, Y; Tailakh, MA | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Horne, AM; Mihov, B; Reid, IR | 1 |
| Akyuz, G; Ata, P; Delil, K; Gencer-Atalay, K; Ozgen, Z; Ozturk, EC; Yagci, I | 1 |
| Chehade, LK; Curragh, D; Selva, D | 1 |
| Chaurand-Lara, J; Facio-Umaña, JA; Mora-Pérez, J; Pacheco-Ruiz, L; Trejo-Campos, JL | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Ralston, SH | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Anastasilakis, AD; Evangelatos, G; Fragoulis, GE; Iliopoulos, A | 1 |
| Du, D; Gu, M; Jin, L; Xu, J; Yang, Z; Zhang, C; Zhao, S; Zhao, T; Zhao, W; Zheng, L | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| Cicchiello, S; De Ponte, FS; Lo Giudice, G; Marino, R; Mummolo, S; Nastro Siniscalchi, E; Scozzaro, C; Squillacioti, A | 1 |
| McConnell, M; Shieh, A | 1 |
| Jakubowski, M; Pokora, M; Ratajczak, M; Sandomierski, M; Voelkel, A; Zielińska, M | 1 |
| Lane, JM; Levin, JE; Nieves, JW; Tutaworn, T; Wang, Z; Yoo, JE | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Gates, M; Hartling, L; Nuspl, M; Pillay, J; Vandermeer, B; Wingert, A | 1 |
| Amigues, C; Breuil, V; Drici, MD; Fresse, A; Gauthier, S; Roux, CH; Vieillard, MH | 1 |
36 review(s) available for risedronic acid and zoledronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
Pharmacological therapy of Paget's and other metabolic bone diseases.
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Osteogenesis; Risedronic Acid; Zoledronic Acid | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
Drugs Used in Paediatric Bone and Calcium Disorders.
Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Calcitriol; Calcium; Child; Denosumab; Diphosphonates; Diuretics; Glucocorticoids; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Osteoporosis; Parathyroid Hormone; Phosphates; Risedronic Acid; Sodium Potassium Chloride Symporter Inhibitors; Vitamin D; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Male; Muscular Dystrophy, Duchenne; Osteoporosis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Vibration; Vitamin D; Weight-Bearing; Zoledronic Acid | 2017 |
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Diphosphonates; Humans; Imidazoles; Network Meta-Analysis; Risedronic Acid; Sodium Fluoride; Zoledronic Acid | 2017 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
Challenges in the treatment of fibrodysplasia ossificans progressiva.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density Conservation Agents; Breathing Exercises; Cushing Syndrome; Female; Humans; Indomethacin; Muscle Stretching Exercises; Myositis Ossificans; Physical Therapy Modalities; Prednisolone; Radiotherapy; Range of Motion, Articular; Risedronic Acid; Vitamin D; Young Adult; Zoledronic Acid | 2019 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapatites; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Zoledronic Acid | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Primary Health Care; Primary Prevention; Risedronic Acid; Systematic Reviews as Topic; Zoledronic Acid | 2023 |
8 trial(s) available for risedronic acid and zoledronic acid
| Article | Year |
|---|---|
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Quality of Life; Risedronic Acid; Zoledronic Acid | 2005 |
Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2006 |
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2007 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome; Young Adult; Zoledronic Acid | 2009 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Menopause; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prednisone; Risedronic Acid; Sex Factors; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Femur Neck; Glucocorticoids; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Young Adult; Zoledronic Acid | 2012 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2013 |
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Double-Blind Method; Endpoint Determination; Female; Femur Neck; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Reproducibility of Results; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
77 other study(ies) available for risedronic acid and zoledronic acid
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents | 2005 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
Topics: Acid Anhydride Hydrolases; Animals; Diphosphonates; Female; Mice; Models, Molecular; Protozoan Proteins; Pyrophosphatases; Quantitative Structure-Activity Relationship; Solubility; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African; Vacuoles | 2005 |
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Pyridines; Quinolines; Structure-Activity Relationship; Terphenyl Compounds | 2006 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
Topics: Alkyl and Aryl Transferases; Binding Sites; Crystallography, X-Ray; Dimerization; Diphosphates; Diphosphonates; Diterpenes; Farnesyltranstransferase; Hydrophobic and Hydrophilic Interactions; Isoenzymes; Ligands; Models, Chemical; Models, Molecular; Molecular Structure; Polyisoprenyl Phosphates; Protein Structure, Secondary; Saccharomyces cerevisiae; Sesquiterpenes; Stereoisomerism; Substrate Specificity; Transferases | 2007 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
Topics: Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line, Tumor; Dictyostelium; Diphosphonates; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Leishmania donovani; Models, Chemical; Plasmodium vivax; Predictive Value of Tests | 2008 |
Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.
Topics: Animals; Anti-Infective Agents; Cattle; Cells, Cultured; Chromatography, Liquid; Cryptosporidiosis; Cryptosporidium parvum; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Fluorescent Antibody Technique; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Prenylation | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids | 2011 |
Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
Topics: Aminopyridines; Aniline Compounds; Antineoplastic Agents; Apoptosis; Catalytic Domain; Cell Survival; Crystallography, X-Ray; Diphosphonates; Drug Design; Extracellular Signal-Regulated MAP Kinases; Geranyltranstransferase; Hemiterpenes; Humans; Models, Molecular; Multiple Myeloma; Organophosphorus Compounds; Phosphorylation; Protein Conformation; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
Topics: Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Diphosphates; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Pyrimidines | 2013 |
Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
Topics: Allosteric Site; Alzheimer Disease; Catalytic Domain; Crystallography, X-Ray; Diphosphonates; Drug Evaluation, Preclinical; Enzyme Inhibitors; Geranyltranstransferase; Humans; Ligands; Neurodegenerative Diseases; Organophosphonates; Phosphorylation; Polymorphism, Single Nucleotide; Pyrimidines; tau Proteins | 2014 |
Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
Topics: Allosteric Site; Catalytic Domain; Diphosphonates; Geranyltranstransferase; Humans; Ligands; Magnesium; Molecular Docking Simulation; Protein Binding | 2015 |
Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.
Topics: | 2015 |
Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Topics: Animals; Calcification, Physiologic; Cell Line; Diphosphonates; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Geranyltranstransferase; Humans; Mice; Molecular Docking Simulation; Osteoclasts; Osteogenesis; RAW 264.7 Cells | 2018 |
Novel benzimidazole phosphonates as potential inhibitors of protein prenylation.
Topics: Benzimidazoles; Humans; Organophosphonates; Protein Prenylation | 2019 |
A guanidinium-based inhibitor of a type I isopentenyl diphosphate isomerase.
Topics: Carbon-Carbon Double Bond Isomerases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escherichia coli; Geranyltranstransferase; Guanidine; Hemiterpenes; Humans; Molecular Structure; Structure-Activity Relationship | 2020 |
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility | 2020 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Remission Induction; Risedronic Acid; Zoledronic Acid | 2005 |
[Optimizing therapy in Paget disease].
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Imidazoles; Mesothelioma; Mice; Phosphorylation; Risedronic Acid; Zoledronic Acid | 2006 |
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Topics: Animals; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Models, Molecular; Molecular Sequence Data; Molecular Structure; Nitrogen; Protein Binding; Protein Conformation; Recombinant Proteins; Risedronic Acid; Zoledronic Acid | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteitis Deformans; Osteoporosis, Postmenopausal; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2006 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid | 2008 |
Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Topics: Algorithms; Binding Sites; Bone Density Conservation Agents; Carcinoma; Computer Simulation; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Farnesyltranstransferase; Humans; Imidazoles; Inhibitory Concentration 50; Magnesium; Models, Chemical; Organophosphonates; Pyridines; Risedronic Acid; Stereoisomerism; Structure-Activity Relationship; Zoledronic Acid | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid | 2008 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteoporosis; Research Design; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid | 2010 |
Differences between bisphosphonates in binding affinities for hydroxyapatite.
Topics: Bone Density Conservation Agents; Chromatography, Liquid; Diphosphonates; Durapatite; Etidronic Acid; Imidazoles; Risedronic Acid; Spectrophotometry, Ultraviolet; Zoledronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid | 2010 |
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Diphosphonates; Endothelial Cells; Etidronic Acid; Geranyltranstransferase; Humans; Imidazoles; Male; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Risedronic Acid; Zoledronic Acid | 2011 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.
Topics: Animals; Antimalarials; Calorimetry; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Erythrocytes; Etidronic Acid; Farnesyltranstransferase; High-Throughput Screening Assays; Humans; Imidazoles; Lipids; Mice; Models, Molecular; Parasitemia; Plasmodium; Plasmodium falciparum; Plasmodium vivax; Protein Binding; Risedronic Acid; Survival Analysis; Terpenes; Zoledronic Acid | 2012 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2012 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Hearing Loss, Sensorineural; Humans; Imidazoles; Male; Middle Aged; Otosclerosis; Retrospective Studies; Risedronic Acid; Speech Perception; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2012 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid | 2014 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infant; Kaplan-Meier Estimate; Logistic Models; Male; Osteogenesis Imperfecta; Pamidronate; Platybasia; Retrospective Studies; Risedronic Acid; Skull Base; Zoledronic Acid | 2015 |
Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.
Topics: Catalytic Domain; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Imidazoles; Molecular Dynamics Simulation; Protein Conformation; Protons; Risedronic Acid; Static Electricity; Zoledronic Acid | 2015 |
On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method.
Topics: Anticoagulants; Area Under Curve; Calibration; Chromatography, Liquid; Diazomethane; Diphosphonates; Humans; Hydrogen-Ion Concentration; Imidazoles; Limit of Detection; Mass Spectrometry; Methylation; Nitrogen; Reproducibility of Results; Risedronic Acid; Solid Phase Extraction; Tandem Mass Spectrometry; Trimethylsilyl Compounds; Zoledronic Acid | 2015 |
Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
Topics: Animals; Apoptosis; Bone Resorption; Borates; Cell Differentiation; Diphosphonates; Glass; Imidazoles; Macrophages; Mice; Microscopy, Electron, Transmission; Nitrogen; Osteoclasts; Osteonecrosis; Oxidative Stress; RANK Ligand; RAW 264.7 Cells; Reactive Oxygen Species; Risedronic Acid; Water; Zoledronic Acid | 2016 |
Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells.
Topics: Breast Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Endocytosis; Female; Humans; Imidazoles; Liposomes; Nitrogen; Risedronic Acid; Zoledronic Acid | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Medication selection and patient compliance in the clinical management of osteoporosis.
Topics: Australia; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Patient Compliance; Physician-Patient Relations; Reminder Systems; Risedronic Acid; Zoledronic Acid | 2016 |
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Logistic Models; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; United States; Zoledronic Acid | 2017 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
Topics: Aged; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2018 |
Bisphosphonate-induced orbital inflammation: more common than once thought?
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Inflammation; Magnetic Resonance Imaging; Middle Aged; Orbital Diseases; Risedronic Acid; Tomography, X-Ray Computed; Zoledronic Acid | 2019 |
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Mexico; Middle Aged; Osteoclasts; Retrospective Studies; Risedronic Acid; Time Factors; Zoledronic Acid | 2019 |
Bisphosphonates in the management of Paget's disease.
Topics: Alendronate; Diphosphonates; Humans; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2020 |
Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report.
Topics: Bone Density Conservation Agents; Conservative Treatment; Disease Management; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2021 |
Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Precipitating Factors; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2022 |
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile.
Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zinc; Zoledronic Acid | 2023 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2023 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Incidence; Osteoporosis; Pharmacovigilance; Risedronic Acid; Risk Factors; Zoledronic Acid | 2023 |